Product Information

Full Name: Retatrutide Lyophilized Powder

Core Mechanism of Action

Retatrutide is a triple GLP-1/GIP/GCGR receptor agonist with broader action pathways than dual-target peptides:

1. Activate three major metabolic receptors simultaneously to strongly suppress appetite and delay gastric emptying

2. Significantly improve insulin resistance, with stronger hypoglycemic and fat-loss effects than tirzepatide and semaglutide

3. Regulate hepatic fat metabolism, inhibit liver lipid synthesis and relieve metabolic disorders related to severe obesity

4. Modulate intestinal hormone secretion to achieve long-term balance of human energy intake and consumption

Main Highlighted Effects

1. Powerful Weight Control

For experiments on intractable obesity and recurring weight rebound. It suppresses hunger signals, greatly reduces appetite, rapidly eliminates visceral and subcutaneous fat, and delivers superior fat-loss effects compared with single-target GLP-1 peptides.

2. Improvement of Severe Glucose Metabolic Disorders

Applied to animal model experiments with refractory insulin resistance and high glycated hemoglobin. It stably controls blood glucose and repairs pancreatic islet secretory function, serving as a cutting-edge research peptide in the metabolic field.

3. Research on Metabolic Disease Models

Used in intervention experiments for animal models of metabolic syndromes including non-alcoholic fatty liver disease, obesity-induced hypertension and hyperlipidemia; improvements in multiple indicators such as inflammation, blood lipids and liver fat can be observed.

4. Research on Endocrine and Metabolic Mechanisms

Widely adopted in pharmacological research focusing on obesity-related endocrine, intestinal flora and energy metabolism mechanisms.

Application Method & Specifications

Administration: Subcutaneous injection only. Reconstitute with sterile buffer, sterilize by filtration and dilute gradiently to prepare stock solution. Oral administration and intravenous injection are strictly prohibited.

Specification Range: RT30 (30mg per vial) is the only mainstream specification at present, suitable for new drug research, preliminary pharmacological experiments and small-batch animal efficacy verification.

Storage Requirements

Dry powder: Sealed and stored frozen at -20°C away from light.

After reconstitution: Must be aliquoted and frozen to avoid repeated freeze-thaw cycles which may destroy the spatial structure of peptides and reduce or lose activity.